Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
Adult
Aged
Antibodies, Monoclonal
/ immunology
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Antibody Affinity
Antigens, Viral
/ immunology
B-Lymphocyte Subsets
/ immunology
Betacoronavirus
/ immunology
Broadly Neutralizing Antibodies
/ immunology
COVID-19
Cell Line, Tumor
Coronavirus Infections
/ immunology
Epitopes
/ immunology
Female
Humans
Immunologic Memory
Immunophenotyping
Male
Middle Aged
Pandemics
/ prevention & control
Pneumonia, Viral
/ immunology
Protein Domains
Protein Interaction Domains and Motifs
/ immunology
Receptors, Coronavirus
Receptors, Virus
/ metabolism
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ chemistry
Journal
Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511
Informations de publication
Date de publication:
07 08 2020
07 08 2020
Historique:
received:
04
05
2020
accepted:
10
06
2020
pubmed:
17
6
2020
medline:
25
8
2020
entrez:
17
6
2020
Statut:
ppublish
Résumé
The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.
Identifiants
pubmed: 32540902
pii: science.abc5902
doi: 10.1126/science.abc5902
pmc: PMC7299281
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Antigens, Viral
0
Broadly Neutralizing Antibodies
0
Epitopes
0
Receptors, Coronavirus
0
Receptors, Virus
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
643-650Informations de copyright
Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.
Références
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
J Struct Biol. 2009 Apr;166(1):95-102
pubmed: 19263523
Cell Rep. 2019 Sep 24;28(13):3395-3405.e6
pubmed: 31553909
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
Nature. 2020 May;581(7807):221-224
pubmed: 32225175
PLoS Med. 2006 Jul;3(7):e237
pubmed: 16796401
Cell Mol Immunol. 2020 Jun;17(6):647-649
pubmed: 32313207
N Engl J Med. 2016 Jan 7;374(1):33-42
pubmed: 26735992
PLoS Pathog. 2013 Sep;9(9):e1003618
pubmed: 24068931
J Pediatr Health Care. 1999 Jul-Aug;13(4):191-5; quiz 196-7
pubmed: 10690084
Antivir Ther. 2018;23(7):617-622
pubmed: 29923831
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Nature. 2019 Feb;566(7744):393-397
pubmed: 30664748
Nat Microbiol. 2016 Nov 14;2:16199
pubmed: 27841852
Nat Methods. 2009 May;6(5):343-5
pubmed: 19363495
EBioMedicine. 2019 Feb;40:574-582
pubmed: 30638863
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Nat Commun. 2016 May 10;7:11544
pubmed: 27161536
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Ultramicroscopy. 1999 Jul;77(3-4):153-61
pubmed: 10406132
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
Nat Commun. 2017 May 15;8:15371
pubmed: 28504265
Nat Med. 2018 May;24(4):401-407
pubmed: 29554084
Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18
pubmed: 32134278
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Clin Infect Dis. 2018 Jan 18;66(3):387-395
pubmed: 29020321
J Struct Biol. 2009 May;166(2):205-13
pubmed: 19374019
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Curr Top Microbiol Immunol. 2013;372:83-104
pubmed: 24362685
Viruses. 2020 Feb 25;12(3):
pubmed: 32106567
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Virology. 1995 Feb 1;206(2):935-44
pubmed: 7531918
Proc Natl Acad Sci U S A. 2014 May 13;111(19):E2018-26
pubmed: 24778221
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Nature. 2020 Aug;584(7819):115-119
pubmed: 32454513
Immunity. 2018 Feb 20;48(2):339-349.e5
pubmed: 29396163
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Curr Opin Virol. 2019 Oct;38:70-80
pubmed: 31421319
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17624-9
pubmed: 25422458
J Immunol Methods. 2008 Jan 1;329(1-2):112-24
pubmed: 17996249
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Front Immunol. 2014 Jun 02;5:250
pubmed: 24917864
J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626
pubmed: 29860496
Cell. 2015 Dec 17;163(7):1702-15
pubmed: 26687358
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Cell. 2020 May 14;181(4):894-904.e9
pubmed: 32275855
Curr Opin Virol. 2019 Feb;34:149-159
pubmed: 30884330
J Struct Biol. 2012 Dec;180(3):519-30
pubmed: 23000701